Aviptadil

N/A

Report date: 2026/02/22 20:00:16
NME

Base Information

Drug NameAviptadil
Drug Alias NameDasKloster 1000-04阿肽地尔Vasoactive intestinal peptideAviptadilumDasKloster 1000 +[13] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionVasoactive intestinal polypeptide receptor 1 agonistsVasoactive intestinal polypeptide receptor 2 agonists
TargetsVasoactive intestinal polypeptide receptor 1Vasoactive intestinal polypeptide receptor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)DyspneaRespiratory Distress Syndrome, Adult +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTurkey
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesUnited Therapeutics CorpMondobiotech
China Registration ClassN/A

Develop Information

Active CompaniesNRx Pharmaceuticals IncNational Institute Of Allergy And Infectious Diseases (Niaid)Centurion Pharma Pvt Ltd
Inactive CompaniesApr Applied Pharma Research Sa
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsDyspneaRespiratory Distress Syndrome, AdultAcute Lung Injury +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG